08 April 2014 / international
Curis and Debiopharm Group™ Report Preclinical Data for Debio 0932 at AACR Annual Meeting 2014 [Read more]
02 April 2014 / international
Evotec and Debiopharm Group™ to collaborate on development of new treatment for cancer [Read more]
06 March 2014 / International
Debiopharm Group™ to Acquire Products or Companies to Expand Activities at Manufacturing Facility in Martigny (Valais, Switzerland) [Read more]
06 March 2014
Debiopharm Group™ to Acquire Products or Companies to Expand Activities at Manufacturing Facility in Martigny (Valais, Switzerland) [Read more]
05 March 2014
Immunexpress Closes USD 6 Million Financing Round led by Debiopharm Group™ [Read more]
13 January 2014
Debiopharm Group™ Announces Completion of Recruitment for Phase III Clinical Study with Triptorelin 22.5 mg in Central Precocious Puberty [Read more]
24 September 2013
Debiopharm Group™ inaugure la « Debiopharm academy » à l’EPFL avec une première conférence sur la médecine personnalisée [Read more]
20 September 2013
Debiopharm Group™ a le plaisir d’annoncer les étudiants choisis pour les Bourses d’excellence [Read more]
17 September 2013
Debiopharm Investment SA entre dans le capital de la start-up de l’EPFL Smallrivers SA, éditeur du service Paper.li [Read more]
07 April 2014
Inhibition of FGFR3-BAIAP2L1 fusion kinase oncogenic potential by CH5183284/Debio 1347, a compound that inhibits FGFR3 kinase activity constitutively activated by BAIAP2L1 BAR domain dimerization [Read more]
07 April 2014
Design and preclinical profile of CH5183284/Debio 1347, a novel orally available and selective FGFR inhibitor acting on a gatekeeper mutant of FGFR2 [Read more]
07 April 2014
FGFR genetic alterations as a potential predictor of the sensitivity to CH5183284/Debio 1347, a selective FGFR inhibitor with a novel chemical scaffold [Read more]
